BY THE DIGITAL HEALTH LEADERS FOR THE DIGITAL HEALTH COMMUNITY
BY THE DIGITAL HEALTH LEADERS 
Dr Reddy's Acquires 6.5% Stake in Israeli Biotech Company Edity January 2, 2024 Reportedly, the Hyderabad-based pharma has picked up 10,14,442 preferred A-1 shares, equivalent to 6.46% of Israel-based Edity's share capital on a fully diluted basis, for $1.9715 per share, by way of conversion of SAFE.
Roche to Acquire LumiraDx's Point-of-Care Technology for $295 Mn January 2, 2024 The ‘to-be’ acquired LumiraDx technology platform offers a wide array of immunoassay and clinical chemistry tests, with potential for additional high medical value tests in the future. Notably, these tests can be stored at room temperature, enhancing their practicality in decentralised healthcare settings.
Pharma Lobby Urges Parallel Drug Approvals in India to Align with Global Markets December 29, 2023 The pharma lobby, OPPI, representing major multinational pharmaceutical companies including Novartis, Roche, AstraZeneca, Sanofi, and Merck, seeks to expedite the drug approval processes, along with pushing for regulations that facilitate the simultaneous filing of marketing approval applications aligned with major global markets.
Health On Cloud Elevates Global Impact with Metaverse Medical Platform Globally December 29, 2023 South Korea- Health On Cloud, an innovator in advanced healthcare solutions, has expanded its metaverse medical consultation platform, CURISALL, and its medical education platform, MEDTIS.
Corewell Health Reports 2nd Data Breach, over 1 Mn Patients Affected December 29, 2023 The breach occurred at HealthEC, which is a population health management platform that provides services to Corewell Health’s southeast Michigan properties, leading to the exposure of patients’ personal and medical information.
Lupin's Allergic Conjunctivitis Treatment Gains USFDA Approval December 29, 2023 Global pharmaceutical giant Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2%.
Turkey’s Bilkent University Unveils AI-Powered Tech for Depression Detection December 28, 2023 Turkey-based Bilkent University researchers have developed an AI-driven technology for detecting signs of depression and conducting behavioral analysis.
Bristol Myers to Acquire RayzeBio in a $4.1 Bn Deal December 28, 2023 This acquisition seeks to establish Bristol’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumours, delivering radioactive payloads to cancer cells in a targeted manner.
Blaize to hit the Bourses with BurTech Acquisition Corp December 27, 2023 Blaize, a global front-runner in purpose-built AI solutions for edge computing, has revealed plans to go public through a definitive agreement with BurTech Acquisition Corp, a publicly traded special purpose acquisition company.
AstraZeneca to Buy China's Gracell Biotech in a $1.2 Bn Deal December 27, 2023 AstraZeneca will also acquire Gracell's cash, cash equivalents and short-term investments of $234.1 million as of September 30, 2023. The deal is expected to close in the first quarter of 2024.
Bristol Myers to Buy Karuna Therapeutics for $14 Bn to Bolster Neuro Portfolio December 27, 2023 This strategic acquisition fits squarely with Briston’s business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need.
HHS Introduces New AI Transparency Rule for Healthcare Tech Firms December 22, 2023 HHS) has introduced a new rule to safeguard data interoperability and patient access in the healthcare sector.
